High Tower Advisors, LLC Nektar Therapeutics Transaction History

High Tower Advisors, LLC

$64.2 Billion
Q2 2024

A detailed history of High Tower Advisors, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, High Tower Advisors, LLC holds 18,608 shares of NKTR stock, worth $25,865. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,608

Previous 19,258 3.38%

Holding current value

$25,865

Previous $17,000 35.29%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.9 - $1.83 $585 - $1,189	-650 Reduced 3.38%	18,608 $23,000
Q1 2024 May 06, 2024	SELL	$0.49 - $0.96 $237 - $465	-485 Reduced 2.46%	19,258 $17,000
Q3 2023 Nov 08, 2023	BUY	$0.51 - $1.05 $255 - $525	500 Added 2.6%	19,743 $11,000
Q2 2023 Aug 14, 2023	SELL	$0.53 - $1.03 $1,131 - $2,199	-2,135 Reduced 9.99%	19,243 $11,000
Q4 2022 Feb 08, 2023	BUY	$2.03 - $4.28 $219 - $462	108 Added 0.51%	21,378 $48,000
Q3 2022 Nov 09, 2022	BUY	$3.04 - $5.14 $33,546 - $56,719	11,035 Added 107.82%	21,270 $68,000
Q2 2022 Aug 10, 2022	BUY	$3.17 - $6.17 $32,444 - $63,149	10,235 New	10,235 $40,000
Q1 2022 May 12, 2022	SELL	$4.16 - $13.72 $43,796 - $144,444	-10,528 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$10.83 - $18.41 $21,865 - $37,169	-2,019 Reduced 16.09%	10,528 $143,000
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $192,782 - $277,890	-14,750 Reduced 54.04%	12,547 $226,000
Q2 2021 Aug 06, 2021	SELL	$16.52 - $20.4 $32,676 - $40,351	-1,978 Reduced 6.76%	27,297 $466,000
Q1 2021 May 10, 2021	SELL	$16.56 - $25.46 $22,521 - $34,625	-1,360 Reduced 4.44%	29,275 $593,000
Q4 2020 Feb 10, 2021	BUY	$15.77 - $19.03 $96,559 - $116,520	6,123 Added 24.98%	30,635 $522,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $15,860 - $23,699	-956 Reduced 3.75%	24,512 $402,000
Q2 2020 Aug 10, 2020	SELL	$16.86 - $23.44 $4,973 - $6,914	-295 Reduced 1.15%	25,468 $589,000
Q1 2020 May 21, 2020	SELL	$14.47 - $27.96 $12,559 - $24,269	-868 Reduced 3.26%	25,763 $460,000
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $20,075 - $29,246	1,265 Added 4.99%	26,631 $569,000
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $42,511 - $91,182	2,514 Added 11.0%	25,366 $462,000
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $33,480 - $39,204	-1,080 Reduced 4.51%	22,852 $811,000
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $82,644 - $121,297	2,617 Added 12.28%	23,932 $805,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $29,821 - $55,517	-980 Reduced 4.4%	21,315 $700,000
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $46,227 - $68,147	-995 Reduced 4.27%	22,295 $1.36 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $224,775 - $507,627	4,860 Added 26.37%	23,290 $1.14 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $548,457 - $1.04 Million	-9,555 Reduced 34.14%	18,430 $1.96 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $186,001 - $488,840	-8,080 Reduced 22.4%	27,985 $1.67 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $57,639 - $77,760	3,240 Added 9.87%	36,065 $866,000
Q2 2017 Aug 14, 2017	BUY	N/A	32,825	32,825 $643,000

Others Institutions Holding NKTR

# of Institutions

139

Shares Held

134M

Call Options Held

32.8K

Put Options Held

55.5K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $260M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.

Account

High Tower Advisors, LLC Nektar Therapeutics Transaction History